The evidence of screening for GDM is insufficient to determine the extent to which screening has an important impact on maternal and neonatal health outcomes. The balance of benefits versus harms remains in question, especially for the large number of women with lower degrees of hyperglycemia. There is no evidence from prospective trials that screening for GDM is a cost-effective strategy. An RCT of screening is necessary to answer the many remaining questions.